

# CONVERT II

## Clinical Trial

---

A trial to evaluate the safety and effectiveness of AeriSeal® System to block collateral ventilation (CV) and convert a severe emphysema patient from CV+ to CV- status.



---

The AeriSeal System is under investigation in the US and its use is limited to this trial.  
AeriSeal System has received CE Mark in Europe and registration from Australian TGA.

This brochure is for physician use only. Not approved by ethics committee for distribution to patients.

 **CONVERT II**  
by pulmonx

# CONVERT II: KEY TOPICS



Study  
Overview



Participant  
Eligibility



Study  
Design

CT

Initial  
CONVERT  
Trial




Clinical  
Trial Sites

# Study Overview

# The Goal

The objective of the CONVERT II Pivotal Trial is to establish the safety and effectiveness of using the AeriSeal<sup>®</sup> System to target and treat the fissural defects that cause collateral ventilation between lung lobes, which preclude some severe COPD/emphysema patients from benefiting from minimally invasive bronchoscopic lung volume reduction (BLVR) treatment with Zephyr<sup>®</sup> Valves.

The CONVERT II Trial will complement the results gained in the [CONVERT Trial](#).



*A technology that can seal fissure gaps offers the chance of improving the lives of many more patients through access to BLVR. You likely have patients who could be eligible for and benefit from participating in the CONVERT II trial. Are you interested in discussing the enrollment process?*

# Methods

The CONVERT II Trial is a multicenter, prospective, single-arm, pivotal study conducted by Pulmonx Corporation.

**200**

PATIENTS WILL  
BE ENROLLED

**35**

STUDY CENTERS  
ACROSS THE US,  
EU AND AUSTRALIA

**2**

YEAR  
FOLLOW-UP

**AeriSeal  
System**

INVESTIGATIONAL  
DEVICE IN THE US

# Participant Eligibility

## Inclusion Criteria

Please consider referring any patient who meets the following criteria:

- ✔ Adults (40-80 years of age)
- ✔ Severe emphysema
- ✔ Stopped smoking (>8 weeks)
- ✔ Have at least one clear target lobe with:
  - $\geq 50\%$  destruction at  $-910\text{HU}$ , and
  - incomplete adjacent fissure ( $\geq 80\%$ ), and
  - heterogenous emphysema (defined as  $\geq 15\%$  difference between the target lobe and the ipsilateral lobe)
- ✔ Collateral ventilation confirmed by the Chartis® System
- ✔  $6\text{MWD} \geq 150\text{m}$  and  $\leq 450\text{m}$
- ✔ Pulmonary rehab completed within 12 months of enrollment

## Exclusion Criteria

Please note that if your patient presents with any of the following, he or she is not an appropriate candidate for the CONVERT II Trial:

- ✘ Prior LVRS, lobectomy or pneumonectomy, lung transplantation
- ✘ 3 or more COPD exacerbations requiring hospitalization within the last 12 months
- ✘ Asthma or chronic bronchitis as the primary diagnosis
- ✘ Ongoing active respiratory infection
- ✘ Requires invasive ventilatory support
- ✘ Pulmonary hypertension
- ✘ Alpha-1-antitrypsin



Would you consider conducting a chart review to help identify appropriate patients for enrollment in the CONVERT II Trial?

## Inclusion Criteria

Please consider referring any patient who meets the following criteria:

- ✓ Adults (40-80 years of age)
- ✓ Severe emphysema
- ✓ Stopped smoking (>8 weeks)
- ✓ Have at least one clear target lobe with:
  - ≥50% destruction at -910HU, and
  - incomplete adjacent fissure (≥80%), and
  - heterogenous emphysema (defined as ≥15% difference between the target lobe and the ipsilateral lobe)
- ✓ Collateral ventilation confirmed by Chartis® System
- ✓ 6MWD ≥150m and ≤450m
- ✓ Pulmonary rehab completed within 12 months of enrollment

## Exclusion Criteria

Please note that if your patient presents with any of the following, he or she is not an appropriate candidate for the CONVERT II Trial:

- ✗ Prior LVRS, lobectomy or pneumonectomy, lung transplantation
- ✗ 3 or more COPD exacerbations requiring hospitalization within the last 12 months
- ✗ Asthma or chronic bronchitis as the primary diagnosis
- ✗ Ongoing active respiratory infection
- ✗ Requires invasive ventilatory support
- ✗ Pulmonary hypertension
- ✗ Alpha-1-antitrypsin




Would you like your own copy of the CONVERT II Pocket Guide to help identify appropriate patients? Would you like an extra one to share with colleagues?

# Study Design

Participants will be evaluated at 14 visits (9 in clinic and 5 via phone) over 2½ years.

In addition, pulmonary rehab must be completed within 12 months of enrollment and following treatment with Zephyr Valves.



Would you like me to send you the Informed Consent?

# Initial CONVERT Trial

# About the Initial CONVERT Trial

A multicenter, prospective, single-arm study is being conducted at 14 clinical centers across Europe and Australia to evaluate AeriSeal System to occlude collateral channels to convert a CV+ lung lobe to having little to no CV-

# Secondary Endpoint

A secondary objective is Zephyr Valve treatment in the CV- converted patients and assessment of clinical outcomes.

Enrollment has been completed and patients are being followed through 1-year post-Zephyr Valve Treatment.

[\(NCT04559464\)](#)

# About the Initial CONVERT Trial

A multicenter, prospective, single-arm study is being conducted at 14 clinical centers across Europe and Australia to evaluate AeriSeal System to occlude collateral channels to convert a CV+ lung lobe to having little to no CV-.

# Secondary Endpoint

A secondary objective is Zephyr Valve treatment in the CV- converted patients and assessment of clinical outcomes.

Enrollment has been completed and patients are being followed through 1-year post-Zephyr Valve Treatment.

[\(NCT04559464\)](#)

# Interim Results CONVERT Trial

**101**

PATIENTS ENROLLED  
AT 14 OUS SITES

**77%**

CONVERSION RATE  
(75/97)

**89%**

TLVR MCID -350mL  
45 days post-ZV  
(62/70)

## SAEs REPORTED THROUGH 12 MONTHS INCLUDED:

Inflammatory response (post-AS)	15.7%
COPD exacerbation	10.8%
Pneumonia	9.8%
Pneumonitis	5.9%
Pneumothorax (post-ZV)	21.1%
Death (9 months post-ZV)	1%

# Clinical Trial Sites

CONVERT II is currently enrolling patients at sites around the world.



Do you need assistance identifying a site near you?

# Questions?

# Thank You



Would you like a copy of the HCP Brochure that provides the information we covered at your fingertips?

Reference: 1. Darwiche K et al. Eur Respir J 2024; 64(Suppl. 68): OA2801.

Pulmonx Corporation, 700 Chesapeake Drive, Redwood City, CA 94063

© 2024 Pulmonx Corporation or its affiliates. All rights reserved. All trademarks herein are the property of Pulmonx Corporation and its affiliates.  
CONVERT II Trial Educational Deck: [CL154EN\\_D](#)

